Zurich (awp) – The Kinarus laboratory has won a patent in the United States on the composition of its experimental treatment KIN001 (pamapimod and pioglitazone). The license, entitled “Pharmaceutical combination for the treatment of cancer” must protect this intellectual property at least until 2037, specifies a press release issued on Tuesday.
This recognition in the country of Uncle Sam is added to the European patent number EP3468604 B1, validated by most countries of the Old Continent.
jh/vj